EnzyPep B.V.

EnzyPep B.V. is an innovation-driven company founded in 2012 and headquartered in The Netherlands. The company's slogan, "Quality by design", reflects its commitment to developing new, sustainable, and cost-effective synthetic routes for the production of pharmaceutically relevant polypeptides and conjugates. EnzyPep's core technology, chemo-enzymatic peptide synthesis (CEPS), integrates classical peptide chemistry with biocatalysis, enabling enzyme-catalyzed ligation reactions in water with unprotected peptide segments. The company operates in the Biotechnology, Health Care, Life Sciences, and Manufacturing industries, positioning itself at the intersection of innovation and healthcare. EnzyPep's dedication to green and sustainable processes aligns with current industry trends towards more environmentally friendly production methods. EnzyPep received its last investment in a Funding Round on 01 January 2014, with contributions from notable investors including Chemelot Ventures, Limburg Startup, and Nedermaas Hightech Ventures. This investment demonstrates the confidence of industry experts in EnzyPep's potential to revolutionize peptide synthesis and contribute to the advancement of pharmaceutical manufacturing. In summary, EnzyPep B.V. stands out as a pioneering force in the development of innovative synthetic routes for pharmaceutical products, leveraging a unique combination of chemistry and biocatalysis. The company's commitment to sustainability, coupled with its strong investor support, positions it as a promising player in the biotechnology and healthcare sectors.